Cost effectiveness associated with helicobacter pylori screening and eradication in patients taking nonsteroidal anti-inflammatory drugs and/or aspirin

Gut and Liver

Volumn 7, Issue 2, 2013, Pages 182-189

  Song, Hyun Jin ^a   Kwon, Jin Won ^b   Kim, Nayoung ^c   Park, Young Soo ^c  

^a Sungkyunkwan University   (South Korea)

^b Kyungpook National University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Cost benefit analysis; Helicobacter pylori; Mass

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; FEMALE; HEALTH STATUS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIDDEN MARKOV MODEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; QUALITY ADJUSTED LIFE YEAR; SCREENING; SENSITIVITY ANALYSIS; SOUTH KOREA;

EID: 84875089412     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2013.7.2.182     Document Type: Article

References (36)

1. Graham DY, Adam E, Reddy GT, et al. Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig Dis Sci 1991;36:1084-1088.
2. Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007;12:333-340.
3. Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009;29:938-946.
4. Jang HJ, Choi MH, Shin WG, et al. Has peptic ulcer disease changed during the past ten years in Korea? A prospective multi-center study. Dig Dis Sci 2008;53:1527-1531.
5. Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007;11:iii-iv, 1-164.
6. Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728-738.
7. Graham DY, Chan FK. NSAIDs, risks, and gastroprotective strategies: current status and future. Gastroenterology 2008;134:1240-1246.
8. Lee JH, Lee YC, Jeon SW, et al. Guidelines of prevention and treatment for NSAID-related peptic ulcers. Korean J Gastroenterol 2009;54:309-317.
9. Lee SW. Current status of health insurance in the treatment of Helicobacter pylori infection. Hanyang Med Rev 2007;27:103-106.
10. Vergara M, Catalán M, Gisbert JP, Calvet X. Meta-Analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411-1418.
11. Lau JY, Sung J, Hill C, Henderson C, Howden CW, Metz DC. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion 2011;84:102-113.
12. Kim JJ, Kim N, Park HK, et al. Clinical characteristics of patients diagnosed as peptic ulcer disease in the third referral center in 2007. Korean J Gastroenterol 2012;59:338-346.
13. Statistics Korea. Complete Life Table 2009 [Internet]. Daejeon: Statistics Korea; c1996 [cited 2010 Nov 21]. Available from: http://kostat.go.kr.
14. Kim N, Kim JJ, Choe YH, et al. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol 2009;54:269-278.
15. Korean Ministry of Health and Welfare Affairs. Korean national health and nutritional examination survey (2007-2009). Seoul: Korean Ministry of Health and Welfare Affairs, 2010.
16. Latimer N, Lord J, Grant RL, et al. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ 2009;339:b2538.
17. Health Insurance Review and Assessment. Medical/dental service fee. Seoul: Health Insurance Review and Assessment, 2011.
18. Health Insurance Review and Assessment. Weighted average price by active ingredient of pharmaceutical product. Seoul: Health Insurance Review and Assessment, 2010.
19. Kim N, Lee MK, Park JH, Nam RH, Choi YA, Min SJ. The incidence and direct medical costs of peptic ulcer disease in Korean tertiary medical center. Seoul: Health Insurance Review and Assessment, 2009.
20. You JH, Lau W, Lee IY, et al. Helicobacter pylori eradication prior to initiation of long-term non-steroidal anti-inflammatory drug therapy in Chinese patients-A cost-effectiveness analysis. Int J Clin Pharmacol Ther 2006;44:149-153.
21. Scheiman JM, Bandekar RR, Chernew ME, Fendrick AM. Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis. Aliment Pharmacol Ther 2001;15:63-71.
22. Leong RW. Differences in peptic ulcer between the East and the West. Gastroenterol Clin North Am 2009;38:363-379.
23. Feinstein LB, Holman RC, Yorita Christensen KL, Steiner CA, Swerdlow DL. Trends in hospitalizations for peptic ulcer disease, United States, 1998-2005. Emerg Infect Dis 2010;16:1410-1418.
24. Dong WG, Cheng CS, Liu SP, Yu JP. Epidemiology of peptic ulcer disease in Wuhan area of China from 1997 to 2002. World J Gastroenterol 2004;10:3377-3379.
25. Drummond MF. Comparing cost-effectiveness across countries: the model of acid-related disease. Pharmacoeconomics 1994;5:60-67.
26. Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975-979.
27. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002;359:9-13.
28. Labenz J, Blum AL, Bolten WW, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002;51:329-335.
29. Go MF. Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2002;16 Suppl 1:3-15.
30. NIH Consensus conference. Helicobacter pylori in peptic ulcer disease. NIH consensus development panel on Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-69.
31. Kurata JH, Nogawa AN. Meta-Analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997;24:2-17.
32. Hunt RH, Bazzoli F. Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment Pharmacol Ther 2004;19 Suppl 1:9-16.
33. Adamsson I, Nord CE, Lundquist P, Sjöstedt S, Edlund C. Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother 1999;44:629-640.
34. de Boer WA, Tytgat GN. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand J Gastroenterol 1995;30:401-407.
35. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-Analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007;25:155-168.
36. Joish VN, Donaldson G, Stockdale W, et al. The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database. Curr Med Res Opin 2005;21:535-544